BACKGROUND: Children with non-Hodgkin lymphoma (NHL) undergo treatment with central nervous system-directed therapy, the potentially neurotoxic effects of which have not been reported in NHL survivors. METHODS: NHL survivors (n = 187) participating in the St. Jude Lifetime Cohort who were 10 or more years from their diagnosis and were 18 years old or older underwent neurocognitive, emotional distress (Brief Symptom Inventory 18), and health-related quality of life (HRQOL) assessments (36-Item Short Form Health Survey). Age-adjusted z scores were compared with community controls (n = 181) and normative data. Treatment exposures were abstracted from medical records. Models adjusted for the age, sex, and time from diagnosis were used to calculate the risk of impairment. RESULTS: The mean ages at evaluation were similar for the survivors and the controls (35.7 ± 8.9 vs 35.5 ± 11.0 years; P = .86). Survivors were 25.2 ± 8.8 years from their diagnosis: 43 (23%) received cranial radiation, 70 (37%) received high-dose methotrexate, 40 (21%) received high-dose cytarabine, and 151 (81%) received intrathecal chemotherapy. Survivors' intelligence and attention were within normal limits; however, their memory, executive function, processing speed, and academics were impaired in comparison with both population norms and community controls (P values < .05). Treatment-related exposures were not associated with neurocognitive function; however, neurocognitive impairment was associated with lower educational attainment, unemployment, and occupational status (P values < .03). Slower processing speed and worse self-reported executive function were associated with symptoms of depression (P values ≤ .003) and poorer HRQOL (P values < .05). CONCLUSIONS: Adult survivors of childhood NHL experience impaired neurocognitive function, which is associated with lower social attainment and poor HRQOL. Early-detection and intervention strategies are recommended. Cancer 2017.
BACKGROUND:Children with non-Hodgkin lymphoma (NHL) undergo treatment with central nervous system-directed therapy, the potentially neurotoxic effects of which have not been reported in NHL survivors. METHODS: NHL survivors (n = 187) participating in the St. Jude Lifetime Cohort who were 10 or more years from their diagnosis and were 18 years old or older underwent neurocognitive, emotional distress (Brief Symptom Inventory 18), and health-related quality of life (HRQOL) assessments (36-Item Short Form Health Survey). Age-adjusted z scores were compared with community controls (n = 181) and normative data. Treatment exposures were abstracted from medical records. Models adjusted for the age, sex, and time from diagnosis were used to calculate the risk of impairment. RESULTS: The mean ages at evaluation were similar for the survivors and the controls (35.7 ± 8.9 vs 35.5 ± 11.0 years; P = .86). Survivors were 25.2 ± 8.8 years from their diagnosis: 43 (23%) received cranial radiation, 70 (37%) received high-dose methotrexate, 40 (21%) received high-dose cytarabine, and 151 (81%) received intrathecal chemotherapy. Survivors' intelligence and attention were within normal limits; however, their memory, executive function, processing speed, and academics were impaired in comparison with both population norms and community controls (P values < .05). Treatment-related exposures were not associated with neurocognitive function; however, neurocognitive impairment was associated with lower educational attainment, unemployment, and occupational status (P values < .03). Slower processing speed and worse self-reported executive function were associated with symptoms of depression (P values ≤ .003) and poorer HRQOL (P values < .05). CONCLUSIONS: Adult survivors of childhood NHL experience impaired neurocognitive function, which is associated with lower social attainment and poor HRQOL. Early-detection and intervention strategies are recommended. Cancer 2017.
Authors: Melissa M Hudson; Matthew J Ehrhardt; Nickhill Bhakta; Malek Baassiri; Hesham Eissa; Wassim Chemaitilly; Daniel M Green; Daniel A Mulrooney; Gregory T Armstrong; Tara M Brinkman; James L Klosky; Kevin R Krull; Noah D Sabin; Carmen L Wilson; I-Chan Huang; Johnnie K Bass; Karen Hale; Sue Kaste; Raja B Khan; Deo Kumar Srivastava; Yutaka Yasui; Vijaya M Joshi; Saumini Srinivasan; Dennis Stokes; Mary Ellen Hoehn; Matthew Wilson; Kirsten K Ness; Leslie L Robison Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-12-29 Impact factor: 4.254
Authors: Kevin R Krull; Robert D Annett; Zhenyu Pan; Kirsten K Ness; Paul C Nathan; Deo Kumar Srivastava; Marilyn Stovall; Leslie L Robison; Melissa M Hudson Journal: Eur J Cancer Date: 2011-03-31 Impact factor: 9.162
Authors: Matthew J Ehrhardt; John T Sandlund; Nan Zhang; Wei Liu; Kirsten K Ness; Nickhill Bhakta; Wassim Chemaitilly; Kevin R Krull; Tara M Brinkman; Deborah B Crom; Larry Kun; Sue C Kaste; Gregory T Armstrong; Daniel M Green; Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Daniel A Mulrooney Journal: Pediatr Blood Cancer Date: 2016-11-15 Impact factor: 3.167
Authors: Anne C Kirchhoff; Kevin R Krull; Kirsten K Ness; Elyse R Park; Kevin C Oeffinger; Melissa M Hudson; Marilyn Stovall; Leslie L Robison; Thomas Wickizer; Wendy Leisenring Journal: Cancer Date: 2011-01-18 Impact factor: 6.860
Authors: Kevin R Krull; Tara M Brinkman; Chenghong Li; Gregory T Armstrong; Kirsten K Ness; Deo Kumar Srivastava; James G Gurney; Cara Kimberg; Matthew J Krasin; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2013-11-04 Impact factor: 44.544
Authors: Kevin R Krull; Yin Ting Cheung; Wei Liu; Slim Fellah; Wilburn E Reddick; Tara M Brinkman; Cara Kimberg; Robert Ogg; Deokumar Srivastava; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2016-06-06 Impact factor: 44.544
Authors: Elizabeth C Bluhm; Cécile Ronckers; Robert J Hayashi; Joseph P Neglia; Ann C Mertens; Marilyn Stovall; Anna T Meadows; Pauline A Mitby; John A Whitton; Sue Hammond; Joseph D Barker; Sarah S Donaldson; Leslie L Robison; Peter D Inskip Journal: Blood Date: 2008-02-07 Impact factor: 22.113
Authors: Ingrid Tonning Olsson; Tara M Brinkman; Mingjuan Wang; Matthew J Ehrhardt; Pia Banerjee; Daniel A Mulrooney; I-Chan Huang; Kirsten K Ness; Michael W Bishop; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: Cancer Date: 2020-01-08 Impact factor: 6.860
Authors: Kevin R Krull; Kristina K Hardy; Lisa S Kahalley; Ilse Schuitema; Shelli R Kesler Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544
Authors: Ellen van der Plas; T Leigh Spencer Noakes; Darci T Butcher; Rosanna Weksberg; Laura Galin-Corini; Elizabeth A Wanstall; Patrick Te; Laura Hopf; Sharon Guger; Johann Hitzler; Russell J Schachar; Shinya Ito; Brian J Nieman Journal: Pediatr Res Date: 2020-11-17 Impact factor: 3.953
Authors: Johanna Mariegaard; Jonathan Wenstrup; Kevin Zi Ming Lim; Pernille Envold Bidstrup; Annika von Heymann; Christoffer Johansen; Gitte Moos Knudsen; Ian Law; Lena Specht; Dea Siggaard Stenbæk Journal: Support Care Cancer Date: 2020-10-28 Impact factor: 3.603
Authors: L M E van Erp; H Maurice-Stam; L C M Kremer; W J E Tissing; H J H van der Pal; A C H de Vries; M M van den Heuvel-Eibrink; B A B Versluys; M van der Heiden-van der Loo; G A Huizinga; M A Grootenhuis Journal: Support Care Cancer Date: 2021-02-01 Impact factor: 3.359
Authors: Katie A Devine; Salome Christen; Renée L Mulder; Morven C Brown; Lisa M Ingerski; Luzius Mader; Emma J Potter; Charlotte Sleurs; Adrienne S Viola; Susanna Waern; Louis S Constine; Melissa M Hudson; Leontien C M Kremer; Roderick Skinner; Gisela Michel; Jordan Gilleland Marchak; Fiona S M Schulte Journal: Cancer Date: 2022-04-18 Impact factor: 6.921
Authors: Ferenc Magyari; István Virga; Zsófia Simon; Zsófia Miltényi; Anna Illés; Karolina Kósa; Tibor Ivánka; Roland Berecz; Anikó Égerházi; Árpád Illés Journal: Support Care Cancer Date: 2022-03-11 Impact factor: 3.359